Leon Chen - 06 May 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Director
Issuer ticker: NRIX
Reported as of: 06 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 May 2021, 19:48:03 UTC
Next SEC filing: 14 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Christine Ring, as Attorney-in-Fact for Leon Chen

Key filing fact

Leon Chen filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 24 May 2021.

Key facts

This page summarizes Leon Chen's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 May 2021, 19:48.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 06 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $27.38
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Footnote F2

The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein.